Impact of Ranolazine on Coronary Microvascular Dysfunction (MICRO) Study

Patients with angina and coronary microvascular dysfunction, without evidence of structural or epicardial coronary disease (Type I CMVD) remain without evidence based treatment options. Previous work has demonstrated that ranolazine can improve angina frequency and stability among patients with Type 1 CMVD however the mechanism remains unclear. Therefore, the objective of this pilot project was to assess the impact of ranolazine on Type I CMVD as measured using an invasive tool to measure global resistance (index of microcirculatory resistance (IMR)).
Source: Cardiovascular Revascularization Medicine - Category: Cardiology Authors: Source Type: research